within Pharmacolibrary.Drugs.ATC.B;

model B02BX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.26999999999999996,
    adminDuration  = 600,
    adminMass      = 0.15,
    adminCount     = 1,
    Vd             = 0.256,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028333333333333335,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Fostamatinib is an orally administered prodrug that is rapidly converted to its active metabolite, R406. It acts as a spleen tyrosine kinase (SYK) inhibitor and is primarily indicated for the treatment of chronic immune thrombocytopenia (ITP) in adults. Fostamatinib was approved by the FDA in 2018 for this purpose and is currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of R406, the active metabolite of fostamatinib, in healthy adult volunteers after single oral dose, both sexes.</p><h4>References</h4><ol><li><p>Martin, P, et al., &amp; Elsby, R (2016). Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. <i>Drugs in R&amp;D</i> 16(1) 93–107. DOI:<a href=&quot;https://doi.org/10.1007/s40268-015-0120-x&quot;>10.1007/s40268-015-0120-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26748647/&quot;>https://pubmed.ncbi.nlm.nih.gov/26748647</a></p></li><li><p>Paik, J (2021). Fostamatinib: A Review in Chronic Immune Thrombocytopenia. <i>Drugs</i> 81(8) 935–943. DOI:<a href=&quot;https://doi.org/10.1007/s40265-021-01524-y&quot;>10.1007/s40265-021-01524-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33970459/&quot;>https://pubmed.ncbi.nlm.nih.gov/33970459</a></p></li><li><p>Baluom, M, et al., &amp; Lau, DT (2013). Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. <i>British journal of clinical pharmacology</i> 76(1) 78–88. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12048&quot;>10.1111/bcp.12048</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23190017/&quot;>https://pubmed.ncbi.nlm.nih.gov/23190017</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BX09;
